Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Buruli ulcer disease: prospects for a vaccine

Abstract

Buruli ulcer disease (BUD), caused by Mycobacterium ulcerans, is a neglected bacterial infection of the poor in remote rural areas, mostly affecting children. BUD is a mutilating disease leading to severe disability; it is the third most common mycobacterial infection in immunocompetent people after tuberculosis and leprosy. It is most endemic in West Africa, but cases have been reported from more than 30 countries. Treatment with antibiotics is possible, long-lasting and requires injections; there are cases of treatment failures, and the disease is prone to resistance. A vaccine against M. ulcerans would protect persons at risk in highly endemic areas, and could be used as a therapeutic vaccine to shorten the duration of treatment and prevent relapses. There is considerable evidence supporting the notion that generation of a vaccine is feasible. This article reviews the present state of the art with special emphasis on the immunology of the infection and the prospects for development of a vaccine.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Adusumilli S, Mve-Obiang A, Sparer T, Meyers W, Hayman J, Small PLC (2005) Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell Microbiol 7:1295–1304. doi:10.1111/j.1462-5822.2005.00557.x

  2. 2.

    Aujoulat I, Huguet-Ribas MP, Koita Y (1996) Buruli ulcer: an ignored public health problem. Dev Sante 125:22–30 (in French)

  3. 3.

    Bahr GM, Chugh TD, Behbehani K, Shaaban MA, Abdul-Aty M, Al Shimali B, Siddiqui Z, Gabriel M, Rook GA, Stanford JL (1987) Unexpected findings amongst the skin test responses to mycobacteria of BCG vaccinated Kuwaiti school children. Tubercle 68:105. doi:10.1016/0041-3879(87)90025-0

  4. 4.

    Belisle JT, Vissa VD, Sievert T, Takayama K, Brennan BJ, Besra GS (1997) Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 276:1420–14222. doi:10.1126/science.276.5317.1420

  5. 5.

    Buntine J, Crofts K (eds) (2001) Buruli ulcer: management of Mycobacterium ulcerans disease. World Health Organization, Geneva

  6. 6.

    Chauty A, Ardant MF, Adeye A, Euverte H, Guédénon A, Johnson C, Aubry J, Nuermberger E, Grosset J (2007) Promising clinical efficacy of streptomycin–rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 51:4029–4035. doi:10.1128/AAC.00175-07

  7. 7.

    Coutanceau E, Marsollier L, Brosch R, Perret E, Goossens P et al (2005) Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell Microbiol 7:1187–1196. doi:10.1111/j.1462-5822.2005.00546.x

  8. 8.

    Coutanceau E, Legras P, Marsollier L, Reysset G, Cole ST, Demangel C (2006) Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer. Microbes Infect 8:2075–2081. doi:10.1016/j.micinf.2006.03.009

  9. 9.

    Coutanceau E, Decalf J, Martino A, Babon A, Winter N et al (2007) Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J Exp Med 204:1395–1403. doi:10.1084/jem.20070234

  10. 10.

    Debacker M, Zinsou C, Aguiar J, Meyers WM, Portaels F (2003) First case of Mycobacterium ulcerans disease (Buruli Ulcer) that followed a human bite. Clin Infect Dis 36:e67–e68. doi:10.1086/367660

  11. 11.

    Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, Scott JT, Dramaix M, Portaels F (2004) Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity. Trop Med Int Health 9(12) 1297–1304

  12. 12.

    Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, Portaels F (2005) Buruli ulcer recurrence, Benin. Emerg Infect Dis 11:584–589

  13. 13.

    Debacker M, Portaels F, Aguiar J, Steunou C, Zinsou C, Meyers W, Dramaix M (2006) Risk factors for Buruli ulcer, Benin. Emerg Infect Dis 12:1325–1331

  14. 14.

    Demangel C, Stinear TP, Cole ST (2009) Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nat Rev Microbiol 7:50–60. doi:10.1038/nrmicro2016

  15. 15.

    Diaz D, Dobeli H, Yeboah-Manu D, Mensah-Quainoo E, Friedlein A et al (2006) Use of the immunodominant 18-kiloDalton small heat shock protein as a serological marker for exposure to Mycobacterium ulcerans. Clin Vaccine Immunol 13:1314–1321. doi:10.1128/CVI.00254-06

  16. 16.

    Dobos KM, Spotts EA, Marston BJ, Horsburgh CR Jr, King CH (2000) Serologic response to culture filtrate antigens of Mycobacterium ulcerans during Buruli ulcer disease. Emerg Infect Dis 6:158–164

  17. 17.

    George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, Lee R, Small PL (1999) Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283:854–857. doi:10.1126/science.283.5403.854

  18. 18.

    Gooding TM, Johnson PDR, Campbell DE, Hayman JA, Hartland E, Kemp AS, Robins-Browne RM (2001) Immune response to infection with Mycobacterium ulcerans. Infect Immun 69:1704–1707. doi:10.1128/IAI.69.3.1704-1707.2001

  19. 19.

    Gooding TM, Johnson PD, Smith M, Kemp AS, Robins-Browne RM (2002) Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infect Immun 70:5562–5567. doi:10.1128/IAI.70.10.5562-5567.2002

  20. 20.

    Gooding TM, Kemp AS, Robins-Browne RM, Smith M, Johnson PD (2003) Acquired T-helper 1 lymphocyte anergy following infection with Mycobacterium ulcerans. Clin Infect Dis 36:1076–1077. doi:10.1086/368315

  21. 21.

    Grietens KP, Um Boock A, Peeters H, Hausmann-Muela S, Toomer E, Ribera JM (2008) It is me who endures but my family that suffers: social isolation as a consequence of the household cost burden of Buruli ulcer free of charge hospital treatment. PLoS Negl Trop Dis 2:e321. doi:10.1371/journal.pntd.0000321

  22. 22.

    Hayman J (1993) Out of Africa: observations on the histopathology of Mycobacterium ulcerans infection. J Clin Pathol 46:5–9. doi:10.1136/jcp.46.1.5

  23. 23.

    Hong H, Demangel C, Pidot SJ, Leadlay PF, Stinear T (2008) Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria. Nat Prod Rep 25:447–454. doi:10.1039/b803101k

  24. 24.

    Hong H, Coutanceau E, Leclerc M, Caleechurn L, Leadlay PF, Demangel C (2008) Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs. PLoS Negl Trop Dis 2:e325. doi:10.1371/journal.pntd.0000325

  25. 25.

    Huygen K (2003) Prospects for vaccine development against Buruli disease. Expert Rev Vaccines 2:561–569. doi:10.1586/14760584.2.4.561

  26. 26.

    Johnson RC, Sopoh GE, Boko M, Zinsou C, Gbovi J, Makoutode M, Portaels F (2005) Distribution de l’infection à Mycobacterium ulcerans (ulcère de Buruli) dans la commune de Lalo au Bénin. Trop Med Int Health 10:863–871. doi:10.1111/j.1365-3156.2005.01465.x

  27. 27.

    Kiszewski AE, Becerril E, Aguilar LD, Kader IT, Meyers WM, Portaels F, Hernandez PR (2006) The local immune response in ulcerative lesions of Buruli disease. Clin Exp Immunol 143:445–451. doi:10.1111/j.1365-2249.2006.03020.x

  28. 28.

    Lagarrigue V, Portaels F, Meyers WM, Aguiar J (2000) Buruli ulcer: risk of bone involvement! A propos of 33 cases observed in Benin. Med Trop 60:262–266

  29. 29.

    Launois P, DeLeys R, Niang MN, Drowart A, Andrien M, Dierckx P, Cartel JL, Sarthou JL, Van Vooren JP, Huygen K (1994) T-cell-epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy. Infect Immun 62:3679–3687

  30. 30.

    Marsollier L, Robert R, Aubry J et al (2002) Aquatic insects as a vector for Mycobacterium ulcerans. Appl Environ Microbiol 68:4623–4628. doi:10.1128/AEM.68.9.4623-4628.2002

  31. 31.

    Marston BJ, Diallo MO, Horsburgh CR Jr, Diomande I, Saki MZ, Kanga JM, Patrice G, Lipman HB, Ostroff SM, Good RC (1995) Emergence of Buruli ulcer disease in the Daloa region of Cote d’Ivoire. Am J Trop Med Hyg 52:219–224

  32. 32.

    Mor N, Lutsky I, Levy L (1981) Response in the hindfoot pad and popliteal lymph node of C57BL mice to infection with Mycobacterium marinum. Isr J Med Sci 17:236–244

  33. 33.

    Nackers F, Johnson RC, Glynn J, Zinsou C, Tonglet R, Portaels F (2007) Environmental and health-related risk factors for Mycobacterium ulcerans disease (Buruli ulcer) in Benin. Am J Trop Med Hyg 77:834–836

  34. 34.

    Noeske J, Kuaban C, Rondini S, Sorlin P, Ciaffi L, Mbuagbaw J, Portaels F, Pluschke G (2004) Buruli ulcer disease in Cameroon rediscovered. Am J Trop Med Hyg 70:520–526

  35. 35.

    Okenu DM, Ofielu LO, Easley KA, Guarner J, Spotts Whitney EA et al (2004) Immunoglobulin M antibody responses to Mycobacterium ulcerans allow discrimination between cases of active Buruli ulcer disease and matched family controls in areas where the disease is endemic. Clin Diagn Lab Immunol 11:387–391. doi:10.1128/CDLI.11.2.387-391.2004

  36. 36.

    Oliveira MS, Fraga AG, Torrado E, Castro AG, Pereira JP, Filho AL, Milanezi F, Schmitt FC, Meyers WM, Portaels F, Silva MT, Pedrosa J (2005) Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice. Infect Immun 73:6299–6310. doi:10.1128/IAI.73.10.6299-6310.2005

  37. 37.

    Pahlevan AA, Wright DJ, Andrews G, George KM, Small PL et al (1999) The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. J Immunol 163:3928–3935

  38. 38.

    Phillips R, Horsfield C, Mangan JA, Laing K, Etuaful S, Awuah P, Nyarko K, Osei-Sarpong F, Biutcehr P, Lucas S, Wansbrough-Jones M (2006) Cytokine mRNA expression in Mycobacterium ulcerans-infected human skin and correlation with local inflammatory response. Infect Immun 74:2917–2924. doi:10.1128/IAI.74.5.2917-2924.2006

  39. 39.

    Portaels F, Elsen P, Guimaraes-Peres A, Fonteyne P-A, Meyers WM (1999) Insects in the transmission of Mycobacterium ulcerans infection (Buruli ulcer). Lancet 353:986. doi:10.1016/S0140-6736(98)05177-0

  40. 40.

    Portaels F, Chemlal K, Elsen P, Johnson PDR, Hayman JA, Kirkwood R, Meyers WM (2001) Mycobacterium ulcerans in wild animals. In: Collins MT, Manning B (eds) Mycobacterial infections in domestic and wild animals. Office International de Epizooties, vol 20. Scientific and Technical Review, Paris, pp 252–264

  41. 41.

    Portaels F, Johnson P, Meyers WM (eds) (2001) Buruli ulcer: diagnosis of Mycobacterium ulcerans disease. World Health Organization, Geneva

  42. 42.

    Portaels F, Aguiar J, Debacker M, Steunou C, Zinsou C, Guédénon A, Meyers WM (2002) Prophylactic effect of Mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli Ulcer). Clin Diagn Lab Immunol 9:1389–1391. doi:10.1128/CDLI.9.6.1389-1391.2002

  43. 43.

    Portaels F, Aguiar J, Debacker M, Guédénon A, Steunou C, Zinsou C, Meyers WM (2004) BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli Ulcer disease. Infect Immun 72:62–65. doi:10.1128/IAI.72.1.62-65.2004

  44. 44.

    Portaels F, Meyers WM, Ablordey A, Castro A, Chemlal K, De Rijk P, Elsen P, Fissette K, Fraga A, Lee R, Mahrous E, Small P, Stragier P, Torrado E, Van Aerde A, Texeira da Silva M, Pedrosa J (2008) First cultivation and characterization of Mycobacterium ulcerans from the environment. PLoS Negl Trop Dis 2:e178. doi:10.1371/journal.pntd.0000178

  45. 45.

    Portaels F, Silva MT, Meyers WM (2009) Buruli ulcer. Clin Dermatol (in press)

  46. 46.

    Pouillot R, Matias G, Mbondji Wondje C, Portaels F, Valin N, Ngoss F, Njikap A, Marsollier L, Fontanet A, Eyangoh S (2007) Risk factors for Buruli ulcer disease in Cameroon. PLoS Negl Trop Dis 1:e101. doi:10.1371/journal.pntd.0000101

  47. 47.

    Prévot G, Bourreau E, Pascalis H, Pradinaud R, Tanghe A, Huygen K, Launois P (2004) Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease. Infect Immun 72:958–965. doi:10.1128/IAI.72.2.958-965.2004

  48. 48.

    Quek TY, Athan E, Henry MJ, Pasco JA, Redden-Hoare J, Hughes A, Johnson PD (2007) Risk factors for Mycobacterium ulcerans infection, southeastern Australia. Emerg Infect Dis Nov 13(11):1661–1666

  49. 49.

    Revill WD, Morrow RH, Pike MC, Ateng J (1973) A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. Lancet 2: 873–877, 95

  50. 50.

    Siegmund V, Adjei O, Nitschke J, Thompson W, Klutse E, Herbinger KH, Thompson R, van Vloten F, Racz P, Fleischer B, Loescher T, Bretzel G (2007) Dry reagent-based polymerase chain reaction compared with other laboratory methods available for the diagnosis of Buruli ulcer disease. Clin Infect Dis 45:68–75. doi:10.1086/518604

  51. 51.

    Silva MF, Portaels F, Pedrosa J (2007) Aquatic insects and Mycobacterium ulcerans: an association relevant to Buruli ulcer control? PLoS Med 4:e63. doi:10.1371/journal.pmed.0040063

  52. 52.

    Smith PG, Revill WDL, Lukwago E, Rykushin YP (1976) The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda. Trans R Soc Trop Med Hyg 70:449–457. doi:10.1016/0035-9203(76)90128-0

  53. 53.

    Stanford JL, Revill WD, Gunthorpe WJ, Grange JM (1975) The production and preliminary investigation of Burulin, a new skin test reagent for Mycobacterium ulcerans infection. J Hyg (Lond) 74:7–16

  54. 54.

    Stienstra Y, Van Der Graaf WT, te Meerman GJ, The TH, de Leij LF, van der Werf TS (2001) Susceptibility to development of Mycobacterium ulcerans disease: review of possible risk factors. Trop Med Int Health 6:554–562. doi:10.1046/j.1365-3156.2001.00746.x

  55. 55.

    Stinear TP, Jenkin GA, Johnson PD, Davies JK (2000) Comparative genetic analysis of Mycobacterium ulcerans and Mycobacterium marinum reveals evidence of recent divergence. J Bacteriol 182:6322–6330. doi:10.1128/JB.182.22.6322-6330.2000

  56. 56.

    Stinear TP, Mve-Obiang A, Small PLC, Frigui W, Pryor MJ, Brosch R, Jenkin GA, Johnson PDR, Davies JK, Lee RE, Adusumilli S, Garnier T, Haydock SF, Leadlay PF, Cole ST (2004) Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci USA 101:1345–1349. doi:10.1073/pnas.0305877101

  57. 57.

    Tanghe A, Content J, Van Vooren JP, Portaels F, Huygen K (2001) Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer. Infect Immun 69:5403–5411. doi:10.1128/IAI.69.9.5403-5411.2001

  58. 58.

    Tanghe A, Adnet PY, Gartner T, Huygen K (2007) A booster vaccination with Mycobacterium bovis BCG does not increase the protective effect of the vaccine against experimental Mycobacterium ulcerans infection in mice. Infect Immun 75:2642–2644. doi:10.1128/IAI.01622-06

  59. 59.

    Tanghe A, Danzy J-P, Pluschke G, Huygen K (2008) Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting. PLoS Negl Trop Dis 2:e199. doi:10.1371/journal.pntd.0000199

  60. 60.

    Tonjum T, Welty DB, Jantzen E, Small PL (1998) Differentiation of Mycobacterium ulcerans, M. marinum, and M. haemophilum: mapping of their relationships to M. tuberculosis by fatty acid profile analysis, DNA–DNA hybridization, and 16S rRNA gene sequence analysis. J Clin Microbiol 36:918–925

  61. 61.

    Torrado E, Adusumilli S, Fraga AG, Small PL, Castro AG et al (2007) Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun 75:3979–3988. doi:10.1128/IAI.00290-07

  62. 62.

    Uganda Buruli Group (1969) Lancet 18th, 111

  63. 63.

    Van der Werf TS, Van der Graaf WT, Tappero JW, Asiedu K (1999) Mycobacterium ulcerans infection. Lancet 354:1013–1018. doi:10.1016/S0140-6736(99)01156-3

  64. 64.

    Van Vooren JP, Drowart A, De Bruyn J, Launois P, Millan J, Delaporte E, Develoux M, Yernault JC, Huygen K (1992) Humoral responses against the 85A and 85B antigens of Mycobacterium bovis BCG in patients with leprosy and tuberculosis. J Clin Microbiol 30:1608–1610

  65. 65.

    Walsh DS, Meyers WM, Portaels FP, Lane JE, Mongkolsirichaikul D, Hussem K, Gosi P, Myint KS (2005) High rates of apoptosis in human Mycobacterium ulcerans culture-positive buruli ulcer skin lesions. Am J Trop Med Hyg 73:410–415

  66. 66.

    Westenbrink BD, Stienstra Y, Huitema MG, Thompson WA, Klutse EO, Ampadu EO, Boezen HM, Limburg PC, Van der Werf TS (2005) Cytokine responses to stimulation of whole blood from patients with Buruli ulcer disease in Ghana. Clin Diagn Lab Immunol 12:125–129. doi:10.1128/CDLI.12.1.125-129.2005

  67. 67.

    Wiker HG, Harboe M (1992) The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol Rev 56:648–661

  68. 68.

    World Health Organization (2000) Buruli ulcer. In: Asiedu K, Scherpbier R, Raviglione M (eds) Mycobacterium ulcerans infection. World Health Organization, Geneva

  69. 69.

    World Health Organization (2004) Provisional guidance on the role specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). World Health Organization, Geneva

  70. 70.

    World Health Organization (2008) Buruli ulcer disease. Mycobacterium ulcerans infection: an overview of reported cases globally. Wkly Epidemiol Rec 83:145–156

  71. 71.

    Yeboah-Manu D, Peduzzi E, Mensah-Quainoo E, Asante-Poku A, Ofori-Adjei D et al (2006) Systematic suppression of interferon-gamma responses in Buruli ulcer patients resolves after surgical excision of the lesions caused by the extracellular pathogen Mycobacterium ulcerans. J Leukoc Biol 79:1150–1156. doi:10.1189/jlb.1005581

Download references

Author information

Correspondence to Kris Huygen.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Huygen, K., Adjei, O., Affolabi, D. et al. Buruli ulcer disease: prospects for a vaccine. Med Microbiol Immunol 198, 69 (2009). https://doi.org/10.1007/s00430-009-0109-6

Download citation

Keywords

  • Buruli ulcer
  • Mycobacterium ulcerans
  • Mycolactone toxin
  • Vaccine
  • Neglected diseases
  • Review